Drug developer 89Bio soars as NASH drug succeeds in mid-stage study
(Reuters) -Drug developer 89Bio Inc said on Wednesday its experimental treatment for liver disease NASH met the main goals of a small mid-stage study, sending its shares 30% higher. The drug, pegozafermin, helped reduce liver scarring known as fibrosis as measured on two different scales in patients with NASH, or nonalcoholic steatohepatitis, trial data showed. NASH, which has no approved treatments, is the fastest-growing cause of liver transplants in developed […]